Merial has launched Equioxx, a new pain management product which the company says is the first COX-2 specific NSAID for horses

Traditional NSAIDs act by blocking the action of both COX-1 and COX-2 enzymes at the same time. Although COX-2 produces prostaglandins associated with both inflammation and pain, COX-1 has a pivotal role in maintaining normal physiological function, so inhibiting this enzyme may have an increased risk of side effects e.g. gastric ulceration. Merial says Equioxx is the only NSAID that is highly COX-2 selective (up to 643 times more selective for COX-2 than COX-1), acting to reduce pain and inflammation but without affecting the COX-1 enzyme at therapeutic levels.

Equioxx contains the active ingredient firocoxib, and Merial says it is proven to be effective at reducing chronic lameness in horses. Appearing in blood plasma within 30 minutes of oral dosing, its pharmacokinetic profile allows once daily dosing. Field studies have confirmed that firocoxib is highly effective at controlling pain and improving function in horses with chronic osteoarthritis.

Equioxx is available as either a low dose injectable solution or a palatable oral paste.

For more information contact Merial Customer Services on 0870 6000 123

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.